X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Packaging & Logistic

Opticooler receives technical approval by Japanese major airlines

Content Team by Content Team
14th February 2022
in Packaging & Logistic, Press Statements
United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers

DoKaSch Temperature Solutions achieved technical approvals for its “Opticooler” active containers with Japan Airlines (JAL) and All Nippon Airways (ANA). Thus, on all flights operated by Japan’s two largest airlines, forwarders can now use the fast available and highly reliable temperature-controlled packaging solution. In addition to a dedicated Japanese subsidiary and a new service station in Tokyo-Narita, the approval of both Japanese major carriers further strengthens DoKaSch Temperature Solutions’ network in the Asia-Pacific region. Given the highest availability on the market and resilience of the Opticooler packaging solution, customers have enhanced options to operate safe and reliable supply chains for temperature-sensitive goods to and from Asia.

The technical approvals allow the Opticooler to be used in the cargo holds of the two airlines’ fleets. Forwarders and pharmaceutical manufacturers in Japan and worldwide are thus benefitting from increasing leasing options for temperature-controlled packaging solutions and can utilize the well-developed international route networks of both carriers. JAL’s and ANA’s schedules connect Japan with Europe, North America, Southeast Asia as well as Australia. The option of using Opticoolers on these routes is hence opening important accesses to the Japanese and worldwide pharma sector. At Narita International Airport for example, both carriers operate a hub where half of Japan’s total pharmaceutical trade is being handled. Freight forwarders also profit from the efficient and capable range of wide body aircrafts of both carriers, which allows the Opticoolers to always be deployed with optimal and reliable flying platforms.

The technical approval follows the opening of a new service station of DoKaSch in 2021 at Tokyo-Narita Airport. The new depot is ready to meet any demand for RKN and RAP Opticooler at any time and immediately. The German company has also established the dedicated Japanese subsidiary DoKaSch Temperature Solutions K.K. with an office in Tokyo in 2021. In addition to its high availability, the Opticooler is an extremely reliable, temperature-controlled packaging-solution. Without depending on dry ice or other refrigerants, the active container can both cool and heat thanks to a self-supporting electrical power generator and full climate control. They maintain the desired temperature level, e.g. between 2° and 8° Celsius at all times and regardless of external climatic and infrastructural conditions. This makes them the ideal solution for the safe transport of highly sensitive and valuable pharmaceutical products that must always be protected from temperature fluctuations.

“The demand for temperature-sensitive goods is increasing in Japan as well as in whole Asia. In addition to reliability and safety, fast availability at any quantity is also crucial, to step up with this trend. Combined with our new Japanese service station directly at the gateway of our new partners Japan Airlines and All Nippon Airways, we can excellently provide these key capabilities to our customers in the Asia-Pacific region,” says Kazuyoshi Kakizawa, Head of DoKaSch Temperature Solutions K.K..

Andreas Seitz, Managing Director of DoKaSch Temperature Solutions, adds: “The new technical approvals by Japan Airlines and All Nippon Airways are a major step for our growth strategy in Asia. Thanks to the new cooperation, we are further expanding our established and dense global network. With its market leading reliability as well as availability, our Opticooler packaging solution will thereby become available to even more customers in Asia as well as worldwide.”

About DoKaSch Temperature Solutions:

DoKaSch is a family-owned supplier of loading equipment to the global aviation industry. With almost 30 years of experience, DoKaSch has acquired a far-reaching set of skills to develop, manufacture, maintain and market all sorts of unit load devices (ULD) for the transportation of goods and luggage in aircrafts around the world.

At DoKaSch Temperature Solutions, we focus on renting out our Opticooler, an inhouse developed air-conditioned temperature-controlled container, to international airlines. The Opticooler is designed to transport and safeguard high value, temperature sensitive cargo such as pharmaceuticals on intercontinental flights. Our Opticooler-Containers ensure that throughout all climate zones the pharmaceutical cargo reaches its destination safe and undamaged.

The “Made in Germany” DoKaSch Opticooler work autonomously with batteries. It is valued for its exceptional reliability and performance at any climatic and weather situation and keeps cargo very accurately within the 2-8°C or 15-25°C range.

Many well-known pharmaceutical companies have been relying on the Opticooler for years as a way to deliver their vital medicines safely, reliably and undamaged to patients around the world.

Previous Post

Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease

Next Post

Envirotainer introduces the RAP for the future - part of the Releye series

Related Posts

Avadel Pharmaceuticals Receives
Drug Development

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

9th June 2025
ACHEMA
Middle East and South Asia

ACHEMA Middle East to Debut in Riyadh in 2026 Trade Show

9th May 2025
Press Statements

APM Steam Highlights Comprehensive HVAC Insulation Services for Biopharmaceutical and Pharmaceutical Facilities

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Americas

Thermo Fisher to acquire Solventum’s Purification & Filtration business for US$4.1bn

4th March 2025
Drug Development

Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

4th March 2025
Next Post
Envirotainer introduces the RAP for the future - part of the Releye series

Envirotainer introduces the RAP for the future - part of the Releye series

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In